Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Andreas Schmid, MD
University of Kansas Medical Center
Principal Investigator - Douglas Conrad, MD
University of California, San Diego
Principal Investigator - Peter Mogayzel, MD, PhD, MBA
Johns Hopkins University
Principal Investigator - Timothy Corcoran, PhD
UPMC Montefiore Hospital
Principal Investigator - William D Bennett, PhD
University of North Carolina, Chapel Hill
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Glasgow, United Kingdom
- Research Site
Kansas City, Kansas, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Chapel Hill, North Carolina, United States
- Research Site
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Jun 2023
- Primary completion
- 22 Jul 2024
- Completion
- 22 Jul 2024
- Last update posted
- 25 Feb 2026
- Registered enrollment
- 35
- Registry id
- NCT05755932
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.